Vaccinex Stock News

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Hea

Fintel reports that Fcmi Parent has filed a 13D/A form with the SEC disclosing ownership of 23.49MM shares of Vaccinex Inc (VCNX).

March 24th presentation to highlight learnings related to pepinemab's mechanism of action in both Huntington's Disease and Alzheimer's Disease March 24th presentation to highlight learnings related to

Shares of Vaccinex, Inc. (NASDAQ: VCNX) are charging higher on February 7 on news that the clinical-stage biotechnology company secured a patent. VCNX stock increased by more than 20% in pre-market tr

Penny stocks to watch with news this month. The post 7 Penny Stocks To Watch With Big News In February; Time To Buy?

Vaccinex (NASDAQ: VCNX ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. Instead, it looks like today's gains come from increased interest fr

While biotech may be the next big thing, making money through it isn't easy. Indeed, investing in biotech stocks is often more of an art than a science.

Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wednesday, March 2, 2022 Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wed

Penny stocks to buy now according to insiders. The post 8 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Insiders are scooping up shares of these penny stocks in 2022. The post 5 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | Pen

The unemployment rate in the Eurozone dropped to a record low of 7% in December from a revised 7.1% level in the previous month, helping the STOXX Europe 600 Index record gains this morning. Investors

Vaccinex Inc (NASDAQ: VCNX ) has announced a private placement of approximately 5.9 million at $1.11 per share for about $6.6 million gross proceeds . The private placement is expected to close on January 31. Participants in the private placement include entities controlled by Maurice Zauderer, President & CEO of Vaccinex, and Albert Friedberg, Vaccinex''s Chairman. Each of them has purchased $2 … Full story available on Benzinga.com

Penny stocks to buy under $5 right now. Are they worth the risk?

The stock price of Vaccinex Inc (NASDAQ: VCNX) increased by over 20% pre-market today. This is why it happened.

During the last session, Vaccinex Inc. (NASDAQ:VCNX)s traded shares were 1.56 million. At the end of the trading day, the stocks price was $1.66, reflecting an intraday gain of 3.11% or $0.05. The 52-week high for the VCNX share is $9.56, that puts it down -475.9 from that peak though still a striking 9.64% gain Vaccinex Inc. (NASDAQ: VCNX) Drops -475.9% From Highs, Now What? Read More »